高级检索
当前位置: 首页 > 详情页

Prevalence and Risk Factors of Fundus Pathology in Patients with Type 2 Diabetes in a Northeastern Chinese Cohort

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]National Clinical Research Center for Ocular Diseases, Wenzhou, China. [2]Eye Hospital, Wenzhou Medical University, Wenzhou, China. [3]Fushun Eye Hospital, Fushun, Liaoning, China. [4]Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University. Beijing Ophthalmology & Visual Science Key Lab, Beijing, China.
出处:
ISSN:

关键词: Fundus pathology prevalence risk factors type 2 diabetes mellitus

摘要:
To assess the prevalence of and risk factors for fundus pathology in patients with type 2 diabetes mellitus (T2DM) in a cohort from northeastern China.Patients were included from the Fushun Diabetic Retinopathy Cohort Study. Patients aged ≥ 30 years with T2DM were recruited between July 2012 and May 2013. Fundus pathology included retinal vascular occlusion (RVO), age-related macular degeneration (AMD), macular pathology, pathologic myopia (PM) and glaucomatous optic atrophy (GOA).A Total of 1998 patients with gradable fundus photographs were included in this study, of whom 388 (19.42%) had fundus pathology regardless of whether they had diabetic retinopathy (DR). There were 187 (9.36%) patients with AMD, 97 (4.85%) with GOA, 67 (3.35%) with macular pathology, 35 (1.75%) with PM and 23 (1.15%) with RVO. Advanced age was significantly associated with AMD (odds ratio (OR), 95% confidence interval (CI): 1.03, 1.01-1.05), macular pathology (OR, 95% CI: 1.06, 1.03-1.09) and GOA (OR, 95% CI: 1.06, 1.04-1.09). A wider central retinal arteriolar equivalent was protective against PM (OR, 95% CI: 0.78, 0.66-0.92). Wider central retinal venular equivalent was a protective factor for PM (OR, 95% CI: 0.75, 0.68-0.82) and GOA (OR, 95% CI: 0.93, 0.87-0.99).One-fifth of these patients in northeast China with T2DM had fundus pathology regardless of whether they had DR, indicating the importance of early screening and long-term follow-up.

基金:
语种:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2023]版:
大类 | 4 区 医学
小类 | 3 区 眼科学
最新[2025]版:
大类 | 4 区 医学
小类 | 4 区 眼科学
JCR分区:
出版当年[2022]版:
Q3 OPHTHALMOLOGY
最新[2023]版:
Q3 OPHTHALMOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2022版] 出版当年五年平均 出版前一年[2021版] 出版后一年[2023版]

第一作者:
第一作者机构: [1]National Clinical Research Center for Ocular Diseases, Wenzhou, China. [2]Eye Hospital, Wenzhou Medical University, Wenzhou, China.
通讯作者:
通讯机构: [1]National Clinical Research Center for Ocular Diseases, Wenzhou, China. [2]Eye Hospital, Wenzhou Medical University, Wenzhou, China. [3]Fushun Eye Hospital, Fushun, Liaoning, China. [*1]Fushun Eye Hospital, No.1 Hu Po Quan Street, Xin Fu District, Fushun, Liaoning 113006, China [*2]National Clinical Research Center for Ocular Diseases, Eye Hospital, Wenzhou Medical University, Wenzhou 325027, China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:23594 今日访问量:3 总访问量:1285 更新日期:2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学附属北京同仁医院 技术支持:重庆聚合科技有限公司 地址:北京市东城区东交民巷1号(100730)